Home/MoonLake Immunotherapeutics/Dr. Christopher K. Morton
DC

Dr. Christopher K. Morton

Chief Financial Officer

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics Pipeline

DrugIndicationPhase
Sonelokimab (M1095)Hidradenitis Suppurativa (HS)Phase 3